cory_ATX — that is really helpful context on Selank and Semax January. Follow-up question: what labs did your doctor order to monitor this?
I am in a similar situation (just started) and trying to set realistic expectations.
To answer PedsEndoPhilly's question specifically:
From a clinical standpoint, Selank and Semax January 2024 is an area where we have good evidence.
The short answer: baseline labs + quarterly monitoring is the standard of care.
The longer answer involves understanding the mechanism of action at the receptor level, which I am happy to elaborate on if helpful.
Relevant to Selank and Semax January 2024 — here is my latest bloodwork comparison:
Key improvements: A1C 8.4% → 5.5%, triglycerides 201 → 101 mg/dL, hsCRP 8.0 → 1.3 mg/L. All on tirzepatide for 17 months.
The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.
Slightly tangential to Selank and Semax January but pete_RVA reminded me — what is the latest on the oral formulations?
I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.